Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PCVX · as of Sep 30, 2025
Ownership Breakdown
296
Institutional Holders
▼ 11 vs Q2
$5.09B
Total Inst. Value
▲ $291.25M vs Q2
144.40M
Shares Outstanding
freeFloat 91.39%
141.29M
13F Shares Held
▼ 6.27M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PCVX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 13.10M | 9.63% | 9.63% | $472.05B | Nov 14, 2025 | ▼ 1.59M |
FMR LLC biological products, (no diagnostic substances) | 12.51M | 9.20% | 9.20% | $450.61B | Nov 13, 2025 | ▲ 358.9K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 12.32M | 9.06% | 9.06% | $443.78B | Nov 7, 2025 | ▲ 323.4K |
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 11.97M | 8.80% | 8.80% | $431.01B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 9.96M | 7.32% | 7.32% | $358.61B | Nov 12, 2025 | ▼ 686.3K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 8.32M | 6.11% | 6.11% | $299.52B | Nov 14, 2025 | ▲ 2.31M |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 5.03M | 3.70% | 3.70% | $181.28B | Nov 14, 2025 | ▲ 78.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 4.79M | 3.52% | 3.52% | $172.39B | Nov 14, 2025 | ▼ 156.3K |
D. E. SHAW & CO., INC. biological products, (no diagnostic substances) | 4.29M | 3.15% | 3.15% | $154.55B | Nov 14, 2025 | ▲ 1.20M |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 3.78M | 2.78% | 2.78% | $136.33B | Nov 14, 2025 | ▲ 411.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
19
Increased
+8.65M shares1
New Positions
first time holders25
Decreased
−11.34M shares0
Sold Out
fully exitedNet shares change (top 50)
2.68M
+8.65M / −11.34M
Net new holders
-5
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PCVX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
5
Sell transactions
0.20
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Wassil Jim CHIEF OPERATING OFFICER | May 1, 2026 | Sale | 2,250 | $56.83 | $127.9K | 160.7K | Form 4 ↗ |
Cowan Elvia SVP, Finance & CAO | Apr 7, 2026 | Sale | 3,000 | $60.00 | $180.0K | 29.0K | Form 4 ↗ |
Wassil Jim CHIEF OPERATING OFFICER | Apr 1, 2026 | Sale | 1,412 | $58.14 | $82.1K | 165.4K | Form 4 ↗ |
Wassil Jim CHIEF OPERATING OFFICER | Apr 1, 2026 | Sale | 838 | $58.93 | $49.4K | 163.0K | Form 4 ↗ |
Cowan Elvia SVP, Finance & CAO | Mar 17, 2026 | Sale | 1,487 | $55.39 | $82.4K | 29.4K | Form 4 ↗ |
Cowan Elvia SVP, Finance & CAO | Mar 17, 2026 | Sale | 405 | $56.26 | $22.8K | 29.0K | Form 4 ↗ |
Dhaliwal Harpreet S. Chief Technical Ops Officer | Mar 9, 2026 | Tax Withhold | 604 | $59.32 | $35.8K | 76.0K | Form 4 ↗ |
PICKERING GRANT CHIEF EXECUTIVE OFFICER | Mar 9, 2026 | Tax Withhold | 3,685 | $59.32 | $218.6K | 496.9K | Form 4 ↗ |
GUGGENHIME ANDREW PRESIDENT AND CFO | Mar 9, 2026 | Tax Withhold | 1,021 | $59.32 | $60.6K | 104.4K | Form 4 ↗ |
Cowan Elvia SVP, Finance & CAO | Mar 11, 2026 | Sale | 2,500 | $58.59 | $146.5K | 30.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Vaxcyte, Inc. (PCVX) is primarily owned by institutional investors, who hold approximately 97.8% of total shares outstanding. Company insiders own approximately 8.61%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Vaxcyte, Inc. is JANUS HENDERSON GROUP PLC, holding approximately 13.10 million shares — equal to 9.63% of outstanding shares — as of September 30, 2025.
A total of 296 institutional investors currently hold PCVX stock, with a combined institutional value of approximately $5.09 billion as of the most recent 13F filing period.
Frequently asked questions
PCVX ownershipVaxcyte, Inc. (PCVX) is primarily owned by institutional investors, who hold approximately 97.8% of shares. The largest shareholder is JANUS HENDERSON GROUP PLC with a 9.63% stake. Company insiders hold 8.61%. Data sourced from SEC Form 13F as of September 30, 2025.